Lipidomics studies on macrophages - bone marrow-derived macrophages treated with 25-hydroxy-cholesterol +/- lipid-depleted media containing compactin
Introduction | Browse | DownloadMouse-over the above links for more information
Treatment details
| LM ID | Analyte | Treatment | Time(hrs) | Sample ID | Value | Units |
|---|---|---|---|---|---|---|
| LMFA01010014 | Myristic acid | Lipid-depleted/compactin | 0.0 | BCD100322A002 | 43.3 | pmol/sample |
| LMFA01010014 | Myristic acid | Lipid-depleted/compactin | 0.5 | BCD100322A005 | 173 | pmol/sample |
| LMFA01010014 | Myristic acid | Lipid-depleted/compactin | 1.0 | BCD100322A009 | 74.8 | pmol/sample |
| LMFA01010014 | Myristic acid | Lipid-depleted/compactin | 2.0 | BCD100322A013 | 61.8 | pmol/sample |
| LMFA01010014 | Myristic acid | Lipid-depleted/compactin | 4.0 | BCD100322A017 | 44.4 | pmol/sample |
| LMFA01010014 | Myristic acid | Lipid-depleted/compactin | 8.0 | BCD100322A021 | 62.6 | pmol/sample |
| LMFA01010014 | Myristic acid | Lipid-depleted/compactin | 12.0 | BCD100322A025 | 54.2 | pmol/sample |
| LMFA01010014 | Myristic acid | Lipid-depleted/compactin | 24.0 | BCD100322A029 | 65.4 | pmol/sample |
| LMFA01010014 | Myristic acid | C | 0.0 | BCD100322A001 | 21.7 | pmol/sample |
| LMFA01010014 | Myristic acid | C | 0.5 | BCD100322A003 | 37.2 | pmol/sample |
| LMFA01010014 | Myristic acid | C | 1.0 | BCD100322A007 | 95.9 | pmol/sample |
| LMFA01010014 | Myristic acid | C | 2.0 | BCD100322A011 | 31.8 | pmol/sample |
| LMFA01010014 | Myristic acid | C | 4.0 | BCD100322A015 | 29.8 | pmol/sample |
| LMFA01010014 | Myristic acid | C | 8.0 | BCD100322A019 | 53.7 | pmol/sample |
| LMFA01010014 | Myristic acid | C | 12.0 | BCD100322A023 | 47.3 | pmol/sample |
| LMFA01010014 | Myristic acid | C | 24.0 | BCD100322A027 | 57 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol + Lipid-depleted/compactin | 0.5 | BCD100322A006 | 138 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol + Lipid-depleted/compactin | 1.0 | BCD100322A010 | 83.7 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol + Lipid-depleted/compactin | 2.0 | BCD100322A014 | 23.1 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol + Lipid-depleted/compactin | 4.0 | BCD100322A018 | 60.1 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol + Lipid-depleted/compactin | 8.0 | BCD100322A022 | 51.5 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol + Lipid-depleted/compactin | 12.0 | BCD100322A026 | 95.5 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol + Lipid-depleted/compactin | 24.0 | BCD100322A030 | 99.8 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol | 0.5 | BCD100322A004 | 76.6 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol | 1.0 | BCD100322A008 | 79 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol | 2.0 | BCD100322A012 | 34.3 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol | 4.0 | BCD100322A016 | 41.2 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol | 8.0 | BCD100322A020 | 78.9 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol | 12.0 | BCD100322A024 | 67.6 | pmol/sample |
| LMFA01010014 | Myristic acid | 25OH-Chol | 24.0 | BCD100322A028 | 36.2 | pmol/sample |